Evaluation of Therapeutic and safety of clemastine fumarate in symptoms and quality of life in secondry Relapsing MS patients
Phase 3
- Conditions
- Multiple sclerosis.Multiple sclerosis
- Registration Number
- IRCT20080901001165N40
- Lead Sponsor
- Bagheiat-allah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
inclusion criteria : To sign the consent form knowingly. At the same time,not in another clinical study. The patient is between 18-50 years old. only have a secondery recurrent MS.
Exclusion Criteria
The patient is pregnant
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Quality of life. Timepoint: baseline,three months after the start of intervention. Method of measurement: Questionnaire.;Symptoms. Timepoint: baseline, three months after the start of intervention. Method of measurement: Examination and diagnostic procedures.
- Secondary Outcome Measures
Name Time Method IgG antibody. Timepoint: baseline and three months after the start of intervention. Method of measurement: elisa.;IgE antibody. Timepoint: baseline and three months after the start intervention. Method of measurement: elisa.;Brain and Spinal Cord Plaques. Timepoint: baseline and three months after the start of intervention. Method of measurement: MRI.;IgE antibody. Timepoint: baselines and three months after the start intervention. Method of measurement: elisa.